PriMera Scientific Medicine and Public Health (ISSN: 2833-5627)

Case Study

Volume 4 Issue 1

To Study the Prevalence and Distribution of HPV High Risk Types in Rural Population of Odisha

Priya Ganeshkumar, Mamata Soren, Sharvari Ozalkar, Harshada Gawali, Ketaki Rajwade, Preeti Arora, Sarjan Shah* and Sanjay Gupte

December 26, 2023

DOI : 10.56831/PSMPH-04-108

View PDF

Abstract

The second most prevalent cancer in women globally and the primary disease in Indian women is cervical cancer, which is mostly caused by infection with the Human Papillomavirus (HPV). Although there are a number of ways to prevent cervical cancer, vaccination is now thought to be the most effective strategy due to the availability vaccinations in the market. The efficiency, immunogenicity, and safety of the vaccination have all been the subject of several research. Particularly in the Indian scenario, there are still concerns and disagreements over immunization requirements, the need for booster shots, and cost- effectiveness.

More than one-fourth of malignancies worldwide associated with infection are caused by the human papillomavirus (HPV). In this paper, the high risk types of HPV in India are summarized, with a particular emphasis on rural parts of Odisha.

The spread caused by human papillomavirus (HPV) is diverse and varies from region to region. Given the limited cross protection provided by the current HPV vaccinations, it is crucial to comprehend the distribution of HPV genotypes among the various populations in order to predict the effectiveness of the present vaccine and develop alternative vaccination strategies. The current study focused into the distribution of HPV genotypes in women in Orrisa, in rural parts.

Keywords: Human Papillomavirus (HPV); cervical cancer; vaccinations

References

  1. Schiffman M., et al. “Human papillomavirus and cervical cancer”. Lancet 370.9590 (2007): 890-907.
  2. Sung H., et al. “Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries”. CA Cancer J Clin 71 (2021): 209-49.
  3. Burd EM. “Human papillomavirus and cervical cancer”. Clinical microbiology reviews 16.1 (2003): 1-17.
  4. Kaarthigeyan K. “Cervical cancer in India and HPV vaccination”. Indian Journal of Medical and Paediatric Oncology 33.01 (2012): 7-12.
  5. Senapati R., et al. “HPV Genotypes distribution in Indian women with and without cervical carcinoma: Implication for HPV vaccination program in Odisha, Eastern India”. BMC infectious diseases 17 (2017): 30.
  6. Sotlar K., et al. “Detection and typing of human papillomavirus by e6 nested multiplex PCR”. Journal of clinical microbiology 42.7 (2004): 3176-3184.
  7. de Roda Husman AM., et al. “The use of general primers GP5 and GP6 elongated at their 3′ ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR”. Journal of general virology 76.4 (1995): 1057- 1062.
  8. Ahmed HG., et al. “Prevalence of human papillomavirus subtypes 16 and 18 among Yemeni patients with cervical cancer”. Asian Pacific journal of cancer prevention: APJCP 18.6 (2017): 1543-1548.
  9. Kaarthigeyan K. “Cervical cancer in India and HPV vaccination”. Indian Journal of Medical and Paediatric Oncology 33.01 (2012): 7-12.
  10. Bosch FX., et al. “Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia”. Vaccine 26 (2008): K1-K16.